Global Drug Discovery Technologies Industry

Global Drug Discovery Technologies Industry

  • April 2021 •
  • 529 pages •
  • Report ID: 5817664 •
  • Format: PDF
Abstract:
- Global Drug Discovery Technologies Market to Reach $74.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$74.3 Billion by 2027, growing at aCAGR of 7.7% over the period 2020-2027. Small Molecule Drug, one of the segments analyzed in the report, is projected to record 7.3% CAGR and reach US$32.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biologics Drug segment is readjusted to a revised 8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $11.9 Billion, While China is Forecast to Grow at 11.5% CAGR
- The Drug Discovery Technologies market in the U.S. is estimated at US$11.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.6 Billion by the year 2027 trailing a CAGR of 11.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 6.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.

- Select Competitors (Total 187 Featured) -
  • Albany Molecular Research, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Covance, Inc.
  • Eli Lilly and Company
  • Evotec AG
  • GenScript USA, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Pfizer, Inc.
  • Viva Biotech (Shanghai) Ltd.
  • WuXi AppTec